), pharmaceutical development 3, 4 and a wide range of algorithm and tool developments and benchmarking (for example, Oncotator ). Available for download and for online exploration, the CGC (COSMIC Cancer Gene Census; see Related links) comprises evidence-based, manually curated summaries of 719 cancer-driving genes (version 86, August 2018) and brings together the expertise of cancer scientists, a dedicated curation team and the comprehensive resources of the COSMIC database (COSMIC Database; see Related links) 9, 10 . To ensure the accuracy and confidence of these data, a conservative approach is adopted to adding new genes to the CGC; genes are included only when evidence for their involvement is clear and unequivocal (Box 1) .
In this Review, we specify which attributes determine the inclusion of a gene into the CGC and how genes could be classified with regard to these attributes in order to better characterize their involvement in oncogenesis. We also describe the new structure of the CGC, which now encompasses two tiers, as well as a new expansion of the CGC, which describes functional characteristics of Tier 1 cancer genes. Finally, we explore how this broad characterization of cancer gene function demonstrates the complexity of cancer genetics, which factors can influence the effect of gene dysfunction in different cancer types and how this knowledge allows investigation of new ways to target known cancer genes by precision oncology.
Defining cancer genes
During oncogenic transformation, the intracellular regulatory network is disturbed, leading eventually to cell reprogramming that promotes unregulated proliferation and adaptation to the tissue environment. Many cellular processes can be disrupted to promote oncogenesis, and somatic or germline genetic mutations are a major and primary causative factor 11 . These genetic events qualitatively or quantitatively alter the function of genes and proteins and in consequence alter the cellular processes in which these proteins participate. and Simon A. Forbes 1 
Abstract | The Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census (CGC)
is an expert-curated description of the genes driving human cancer that is used as a standard in cancer genetics across basic research, medical reporting and pharmaceutical development. After a major expansion and complete re-evaluation, the 2018 CGC describes in detail the effect of 719 cancer-driving genes. The recent expansion includes functional and mechanistic descriptions of how each gene contributes to disease generation in terms of the key cancer hallmarks and the impact of mutations on gene and protein function. These functional characteristics depict the extraordinary complexity of cancer biology and suggest multiple cancer-related functions for many genes, which are often highly tissue-dependent or tumour stage-dependent. The 2018 CGC encompasses a second tier, describing an expanding list of genes (currently 145) from more recent cancer studies that show supportive but less detailed indications of a role in cancer.
Knowledge of which mutations affect the function of a gene and what consequence they induce allows the generation of a mechanistic and functional causal chain of events leading to the development of a neoplasm. This knowledge is being successfully applied to design therapies specifically targeting proteins altered by somatic and germline mutations to drive cancer, with well-known examples including vemurafenib, an inhibitor of V600E-mutant BRAF 12 , and olaparib, which induces synthetic lethality in cancer cells with mutations in BRCA1 or BRCA2 (ref.
13
).
While a wide range of mutations and their consequences have been described across human cancer, driver mutations will typically result in dysfunction, usually via protein structure change; dysregulation, altering regulatory signals that control gene expression; or complete abrogation, which occurs when the whole tumour-suppressor gene (TSG) is deleted. Therefore, to understand the impact of mutation on disease progression, it has to be determined which genes have functions that can be altered to potentially drive or inhibit tumour development.
The CGC has been built to address these challenges and support the wide variety of cancer research occurring around the world. It describes genes functionally associated with hallmarks of cancer 14, 15 and characterized (in most cases) by somatic or germline mutations in their coding regions, which change the resulting proteins' sequences and affect their function.
The entire CGC is under constant scrutiny to provide an up-to-date resource of the impact of protein dysfunction or dysregulation caused by gene mutation. Each gene has been classified across three categories (oncogene, TSG and/or fusion gene) depending on its somatic mutation profile and functional role in oncogenesis. To classify a gene as an oncogene, evidence is required that the activity of the gene product can drive cancer and that alterations resulting in gain of function occur in cancer samples. By contrast, to identify a TSG, alterations resulting in loss of function are sought in tumours, with experimental evidence reporting a cancer-suppressive function of the wild-type gene product.
Gene fusions form a specific class of genetic alteration associated with specific functional consequences. They usually arise as a consequence of genomic structural rearrangements and involve two distinct genes, forming a new chimeric gene with novel or dysregu lated function 16 ; many oncogenic fusions can be described as independent neomorphic oncogenes. The CGC describes how fusion events impact the function of each fusion partner and the contribution of each partner towards the transforming capability of the fusion ( fig. 1 ). The consequence of gene fusions sometimes allows each partner to be classified as having TSG or oncogene function, and these genes are identified as such in the CGC (fig. 1a) . Alternatively, one partner may constitute only a minor genetic element, contributing only a regulatory feature or structural domain but not functioning as an oncogene or TSG on its own ( fig. 1b-d) . Therefore, to incorporate these genes that are crucial for the gain of transforming capacity by the fusion proteins but that cannot be classified as TSGs nor oncogenes on their own, this third functional category of the CGC was created. 
Box 1 | Curation process used for the Cancer Gene Census
The Cancer Gene Census (CGC) curation process is described below and in the figure:
• 
Gain of function
A type of mutation resulting in an altered gene product with intensified activity or with a new biological function (neomorphic mutation).
Loss of function
A type of mutation resulting in an altered gene product with lower or no biological function.
Building a broader perspective
The CGC comprises two tiers, and inclusion in either of these depends on the strength of evidence supporting the involvement of each gene in oncogenesis. 22 , has evidence of only one recurrent missense mutation (D109G) in renal carcinoma provided by one study 23 and only a few frameshift or nonsense mutations that could support tumour-suppressing activity 24 . As such, this gene was placed into Tier 2 of the CGC.
Tier 2 additionally incorporates fusion gene partners that are of unclear consequence but that disrupt the sequence of a known oncogenic partner, giving it transforming ability ( fig. 1d ). An example of such behaviour is KIAA1549, a fusion partner of BRAF in glial and glioneuronal neoplasms. The KIAA1549-BRAF fusion protein is present in 66% of pilocytic astrocytomas and has the active carboxy-terminal kinase domain of BRAF without the amino-terminal autoregulatory domain, thus resulting in constitutively active BRAF expressed under the control of the KIAA1549 promoter 25 ( fig. 1d ).
While the oncogenic activity of BRAF in this fusion is well recognized, and the frequent recurrence of this rearrangement demonstrates that it is an important event in these malignancies, the mode of action of the KIAA1549 coding gene is unclear in this case.
The current CGC (version 86, August 2018) describes 719 genes across two tiers ( fig. 3b ). Of these, 554 are clearly classified as a TSG and/or an oncogene; however, there is substantial overlap, with genes playing different roles between tissues, disease states and different environmental stresses. Below, we discuss some of the striking observations that are possible only via such a broad, deeply descriptive curation effort as the CGC.
Describing functions of cancer genes
To determine the functional role of each CGC gene in oncogenesis, an extensive literature review is performed (and is continually underway) to include new discoveries in cancer genetics. Experimental data from published literature are evaluated and curated in order to describe the oncogenic impact of each gene, and the ten hallmarks of cancer 15 are used to standardize functional categorization for each gene. Widely accepted as the ten major attributes of oncogenesis, the cancer hallmarks allow oncogene. An example of this type of mechanism is seen with QKI-MYB. In angiocentric glioma, MYB is activated by truncation and the influence of the QKI enhancer, and thus, QKI loses its tumour-suppressive function 105 . b | Genes that, after fusion, upregulate an oncogene through donation of a regulatory element (for example, an active promoter, enhancer or activating domain) are included in Tier 1. An example of this type of mechanism is seen with BCR-ABL1. In this fusion (also known as the Philadelphia chromosome), BCR, which is neither a TSG nor an oncogene, simply provides an oligomerization domain, which enables constitutive activation of ABL1 (ref.
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c | A fusion partner that only deactivates a TSG by disrupting its sequence is classified as a Tier 2 Cancer Gene Census gene if it is recurrently involved in a fusion. An example of this type of mechanism is seen with CIITA-RALGDS. In Hodgkin lymphoma, this fusion results in the amino-terminal part of CIITA , which loses its tumour-suppressive function, fused in an out-of-frame fashion to RALGDS, which is neither a TSG nor an oncogene in this case 106 . d | A fusion may also result in hyperactivation of an oncogene owing to loss of an autoinhibitory domain, which is replaced by a fusion partner. An example of this type of mechanism is seen with KIAA1549-BRAF. In pilocytic astrocytoma, the aminoterminal BRAF autoregulatory domain 25 is lost in the fusion protein, resulting in constitutively active BRAF expressed under the control of the KIAA1549 promoter , combine both mechanistic and functional descriptions of cancer gene activity with manually curated evidence from the literature. Functional annotations define whether each gene in its wild-type form has a stimulating or suppressive effect on individual cancer hallmarks and provide immediate access to the relevant literature source via PubMed. These annotations are curated from a continually expanding range of review and research articles, currently encompassing over 1,600 articles and growing rapidly. New graphics have been created to ensure this information is easily accessible online and simple to interpret (fig. 4) .
In addition to the ten hallmarks of cancer, further descriptions take into account roles in additional biological processes that are relevant for cancer but not covered by the hallmarks, such as cell division, differentiation, global regulation of gene expression, senescence and impact of mutation on gene or protein function. The functional description of how each mutated gene and protein causes cancer is a continual and ongoing process, with approximately half the CGC Tier 1 genes already described in both functional and mechanistic terms at the time of this Review. To avoid misrepresenting the role of a gene, functional summaries are added only when manual curation compiles enough information to illustrate the full known spectrum of the function of each gene.
Functional complexity of cancer genes
The recent expansion of the CGC to include functional annotations allows for a deeper and broader insight into genetic and physiological causes of cancer. In the new hallmark pages, all possible ways a gene could be involved in oncogenesis are comprehensively overviewed; no indications are made to rank the importance of each function, as this can change rapidly according to cancer type and stage and can be different for different mutations in the gene. Curation aims to be comprehensive, combining all literature evidence for the involvement of a gene in relevant cellular processes; even when infrequently affected, these processes may still contribute to cancer. This creates a robust and broad perspective on the function of each gene in cancer and can highlight unexpected and targetable aspects of their activity.
Most of the genes in Tier 1 of the CGC have a long track record of published evidence on their function. Although in many cases the majority of research is focused on just one of the many functions of a gene, this exhaustive curation approach describes a broader range of their functionality. Analysis of this information shows that the traditional distinction of TSG and oncogene is often not sufficient to represent the complexity of cancer genetics and that objective curation of all genetic functionality provides unique insights into how each gene can contribute differently to multiple forms of human cancer.
Different roles via distinct hallmarks.
One of the most striking features observed by examining the hallmark pages is that very few genes are limited to impacting just a single hallmark of cancer. Indeed, many CGC genes have the ability to both promote and suppress cancer through their impact on multiple different hallmarks of cancer. This functional complexity originates from the well-known fact that many genes have multiple functions and are involved in numerous biological pathways with variable relevance for the development of diverse types of cancer. In consequence, different genetic alterations affecting the same gene may result in differing cellular dysfunction. Many well-known cancer genes belong to this category, contradicting the simplistic assumption implied by the traditional oncogene or TSG gene classification that inactivating mutations are pathogenic only if a gene is described as a TSG or only gain-of-function mutations are worth investigation in known oncogenes. The functional annotation of CGC genes enables identification of the genes that do not follow this simple pattern.
A good example of such a gene is ATR, which is usually assumed to be a TSG through its core function as a cell cycle checkpoint kinase and regulator of DNA damage repair, but it may also exhibit anti-apoptotic activity at mitochondria in response to ultraviolet irradiation 26 . In the cell, ATR occurs in two isoforms: the trans-isomer is responsible for the cell cycle checkpoint pathway and DNA repair coordination in the nucleus 26 , while the cis-isomer localizes to the cytoplasm and suppresses cytochrome c release in the mitochondria, negatively regulating apoptosis. During isomerization (performed by PIN1), pro-survival cis-ATR is converted to the trans-isoform and relocated to the nucleus. Exposure to ultraviolet light inactivates PIN1 and thus shifts the balance between the two isoforms towards the cis-isomer, delaying apoptosis 27 . This apoptotic response delay, which allows the nucleotide excision repair (NER) system to revert the ultraviolet-induced DNA damage, can potentially be hijacked by the cancer cell, which may be the reason for frequent overexpression and amplification of ATR in multiple cancers 28 . Another example, RB1 (ref. 29 ), an archetypal TSG, may in certain circumstances also support tumour development. Extensively researched and described as a negative regulator of the cell cycle, RB1 is usually inactivated by truncating mutations that lead to uncontrolled cell divisions in cancers. However, in its hyperphosphorylated form, the RB1 protein sequesters and deactivates a pro-apoptotic nuclear phosphoprotein, ANP32A, inhibiting apoptosis 30, 31 . This anti-apoptotic function may explain the observation in patients with muscle-invasive bladder cancer that RB1 expression is associated with higher resistance to radiotherapy 32 . In contrast to ATR and RB1, which are most often described in the context of their tumour-suppressing activity, the gene RAC1 is best known as a positive regu lator of angiogenesis and metastasis 33 as well as proliferation 34, 35 in cancers. Again, in opposition to this cancer-promoting role, RAC1 has also been shown to protect from ultraviolet light-induced skin carcinogenesis as a protein necessary for the induction of an effective DNA damage response 36 . These few examples begin to suggest that cancer arises through complex multidirectional modulation of cellular processes associated with hallmarks of cancer rather than through simple promotion of all hallmarks. They also demonstrate that certain cellular processes important for oncogenic transformation are connected not only through global coordination of relevant pathways but also on a very basic level by one gene having multiple functions associated with these processes. It is also clear that dysfunction of the same gene can be a driving event in one type of cancer while also being opposite or meaningless in another. While it has been understood for some time that a gene may play context-dependent roles across cancers, it is through only large-scale deep curation, which underpins the CGC, that the sheer extent of this phenomenon can be appreciated.
Mutation-specific effects. Clearly, the role of any particular gene in a specific cancer type is determined by the mutations affecting that gene, as well as selective pressures on the cell carrying that mutation.
Neomorphic oncogenes are the most notable examples of how a specific genetic change may define the role of a gene in oncogenesis. Rather than suppressing or potentiating existing functions of the gene, neomorphic mutations result in a gain of a completely new function that can alter signalling and metabolic pathways within the cell and change the structure of cellular networks 37 . For example, the protein encoded by PIK3CA, the PI3K catalytic subunit p110α, normally binds to p85, which stabilizes it and controls its enzymatic activity. This control of p110α activation is abrogated by the E545K mutation in the helical domain of the protein. This mutation enables the abnormal interaction between p110α and insulin receptor substrate 1 (IRS1), which also stabilizes p110α but in a manner independent of signals controlling p85, resulting in constitutive activation of the PI3K pathway and increased cell proliferation, survival and motility 38 . Another highly recurrent p110α mutation -H1047R -increases the protein activity through alteration of its catalytic site without generating new protein functions or interactions, but it also results in upregulation of PI3K signalling. However, these two mutants have slightly different phenotypic impacts, with the helical domain mutant (E545K) giving the cells additional metastatic capacity 39 . As another example, the IDH1 gene encodes a Krebs cycle enzyme, isocitrate dehydrogenase, that catalyses NADPH-dependent reversible decarboxylation of isocitrate to α-ketoglutarate. A single substitution, R132H, in the protein encoded by this gene alters this activity. Owing to the decreased affinity of this mutated enzyme to bind isocitrate and the increased affinity for NADPH caused by the substitution, α-ketoglutarate is reduced to 2-hydroxyglutarate (2HG) during the catalytic cycle 40 . This 2HG acts as a competitive inhibitor of α-ketoglutarate-regulated enzymes, including histone demethylases and the TET family of 5-methlycytosine hydroxylases and thus reshapes the epigenetic landscape of the cell 41 , and this has been shown to promote gliomas and AML 42, 43 . A similar effect was observed in cancer cells carrying mutations in IDH2, which occur more frequently in AML than do IDH1 mutations 42 . As illustrated by these cases, different alterations of the same gene may have distinct impacts on oncogenesis, and they may result in new physiological processes that drive cancer. This demonstrates the need for new resources that would describe the impact of not just each gene but also each mutation on cancer. Owing to the large amount of data involved (currently, over 5 million coding mutations are described in COSMIC), several bioinformatic approaches are ongoing. However, expert manual curation is an essential support for such broad in silico techniques, as vast qualitative information is contained in the scientific literature. Future combinations of the CGC, COSMIC and in silico methods may prove to be the best ways to understand genetic impact across cancer, as well as to guide future therapeutic research via disease-specific functional descriptions.
Tissue-dependent roles. While the type of genetic change is an important factor determining protein dysfunction, in numerous cases, it is the tissue or cell type in which the transformation occurs that also defines how a gene will drive tumour development 44 . Tissue specificity arises as a result of distinct gene expression, chromatin organization or regulation by endocrine and paracrine signalling and determines which functions provide a given cell type with a growth advantage. As this effect could be achieved through activation or inactivation of a given gene, the cell type may also determine the type of genetic alterations (that is, gain of function or loss of function) that are observed in that gene in cancer samples from that tissue.
A surprising number of genes described in the CGC (currently numbering 72) have been shown, when mutated, to possess either tumour-promoting or tumour-suppressing activity in different tissues. This diverse impact may reflect a variety of tissue-specific microenvironmental dependencies.
Solid and haematological tumours may also involve the same gene in different ways, as evidenced by the occurrence of different mutations affecting different gene functions in different cancer types. For example, DNM2 is a TSG in T cell acute lymphoblastic leukaemia, where loss-of-function mutations in its GTPase domain inhibit endocytosis of the interleukin-7 (IL-7) receptor. The increased density of the surface IL-7 receptor restrains the differentiation of leukaemic cells, driving the disease 45 . Conversely, this same gene is frequently overexpressed in advanced stages of prostate cancer, where it is associated with poor prognosis 46 . In vitro experiments using pancreatic cancer cells have shown that DNM2 promotes invasion by stabilizing VAV1, a RAC1 guanine nucleotide exchange factor that promotes RAC1 activation, leading to increased cancer cell migration and invasive capacity 47 . The importance of these two distinct functions for transformation might be determined by the differences between the two cell types: IL-7 signalling is most likely not crucial in pancreatic or prostate cell transformation, while invasion by leukaemic cells is likely controlled by mechanisms distinct to invasion by solid tumours owing to the inherent presence of leukaemic cells within the circulatory system and the innate anchorage-independent survival of these cells.
Having a function that is highly dependent on the bio logical context particularly applies to genes acting on a broader, cellular level, for instance, genes that encode proteins modifying multiple targets leading to a global change of chromatin structure or gene expression patterns. DROSHA, which encodes a protein responsible for maturation of microRNAs (miRNAs) 48 , is often inactivated in Wilms tumour by the E1147K missense somatic mutation 49 . This alteration causes lower tumour-suppressing miRNA production through a dominant negative mechanism 50 . As these miRNA products modulate the levels of multiple mRNAs (which a b 108 encoded by cancer genes on the hallmarks of cancer in simple graphical form. If the wild-type protein function promotes a process related to cancer, it is marked within the green outer ring. A protein suppressing a hallmark of cancer in its wild-type form is marked within the blue outer ring. b | The alternative presentation of the summary of PTEN functions on the CGC website 108 shows how an alteration resulting in gain or loss of function of a gene may impact each of the hallmarks. As wild-type PTEN promotes (P) growth suppression, an inactivating PTEN mutation will lead to increased proliferation of mutant cells. S, suppresses. Cancer hallmarks image in part a adapted with permission from ref. 
Wilms tumour
Another name for nephroblastoma, a malignant embryonal neoplasm of the kidney.
vary substantially between tissues), it is very likely that in other cancers the role of DROSHA will be different. Indeed, in non-small-cell lung cancer (NSCLC), DROSHA is frequently amplified, which correlates with reduced survival 51 , indicating a likely oncogenic function for this gene and its miRNA products. It should be noted that even though the dysfunction of DROSHA drives cancer, the mechanism of this process is not related to any of the classic hallmarks of cancer 15 . For that reason, on the hallmark pages, we also describe the participation of a gene in cancer-driving genome-wide regulation of gene expression through changes of global epigenetic patterns and noncoding RNA biosynthesis 52 . Similarly, ubiquitylation alters the levels and activity of multiple proteins 53 , and its impact is also tissue-dependent. For example, mutations that inactivate the BIRC3 ubiquitin ligase induce transformation of NSCLC cells 54 , while in glioblastoma, the upregulation of BIRC3 ubiquitin ligase activity enables escape from apoptosis and is associated with worse outcome 55 .
In the same way, owing to the wide spectrum of changes to cellular metabolism introduced by genes encoding regulators of hormone responses (such as ESR1 (refs 56,57 ) and TBL1XR1 (refs 58,59 )) or epigenetic modifiers (such as CHD4 (refs 60,61 ), KDM6A 62, 63 and TET1 (refs 64,65 )), the role of these genes in cancer is highly tissue-specific. An excellent example of a gene that plays roles in both hormonal and epigenetic regulation, as well as in both tumour promotion and suppression, is NCOR2. In response to hormones including oestrogens, androgens and thyroid hormones and signalling molecules such as retinoic acid [66] [67] [68] , NCOR2 recruits histone deacetylase 3 (HDAC3) to chromatin and promotes histone deacetylation, which changes the gene expression patterns in the cell 69 . Disruption of NCOR2-driven deacetylation results in global histone H4 lysine 5 (H4K5) hyperacetylation and DNA damage 70 , and loss of this protein has been detected in samples from patients with non-Hodgkin lymphoma and has been shown to promote transformation of immortalized fibroblasts 71 and prostate cancer cells 66 . By contrast, in oestrogen-dependent breast cancer cells, NCOR2 activity is essential for oestradiol-induced progression through the G1-S transition, and its loss results in apoptosis 68 . NCOR2 additionally represses expression of pro-apoptotic genes and delays DNA damage-induced caspase activation 68, 72 , which can positively drive oestrogen-dependent breast cancer development.
Cellular responses can be further modified by external factors, such as pathogens, leading to alteration or even inversion of cancer gene function. The NER proteins ERCC4 and ERCC5 protect the genome from damage, and germline mutations in ERCC4 and ERCC5 are associated with xeroderma pigmentosum (group F and group G, respectively) syndromes involving an increased susceptibility to skin cancers 73, 74 . However, in gastric epithelium infected by Helicobacter pylori, the activity of these genes is directly responsible for infection-associated DNA double-strand breaks. Contact of the epithelial cells with H. pylori results in activation of the NF-κB transcription factor by bacterial cytotoxin-associated gene (Cag) proteins in an epithelial β1 integrin-dependent manner. Activated NF-κB binds to its specific promoters and recruits the ERCC4 and ERCC5 NER endonucleases 75 . These two endonucleases have been implicated in transcription-associated generation of transient DNA breaks that help achieve optimal chromatin looping for the efficient transcription of the RARB gene in HeLa cells 76 . The interaction of NF-κB, which is constantly activated by bacterial proteins, and ERCC4 and ERCC5 stimulates the expression of antiapoptotic genes 75 . Additionally, multiple nicks are generated in the local DNA by ERCC4 and ERCC5, turning into DNA double-strand breaks when closely spaced. These are subsequently repaired through error-prone non-homologous end joining 75 . This demonstrates the need for careful interpretation of mutated ERCC4 and ERCC5 variants in gastric cancer, as these proteins can either remove or, in the presence of H. pylori pathogens, generate somatic mutations driving gastric cancer.
Tumour stage matters. The development of many malignant solid tumours includes an initial in situ stage before the tumour invades surrounding tissues and becomes metastatic. These phases are characterized by slightly different requirements for cellular processes: for example, increased cell motility gives limited advantage to tumour cells during initial transformation, while it is crucial for invasion. It is also becoming clear that the activity of genes protecting normal cells from oncogenic transformation may actually be beneficial for an invasive tumour, while genes promoting initial stages of transformation may limit metastasis. The transcription factor FOXA1 illustrates this well. Involved in oestrogen and androgen signalling 77 , FOXA1 promotes cell proliferation in multiple breast cancer 78 and prostate cancer cell lines 79, 80 but inhibits epithelial-to-mesenchymal transition (EMT) in prostate 80 , pancreatic 81 and breast 82 cancer cells. While FOXA1 hyperactivity drives tumour growth in situ, the inhibition of EMT reduces the invasive capability of the tumour, and it is likely that this must be overcome to enable metastasis.
Some TSGs may also promote invasion and metastasis when active in later stages of tumorigenesis. For instance, APC, in addition to repressing the WNT signalling pathway (limiting cell proliferation and self-renewal capacity 83 ), can also promote cell migration in the intestinal epithelium of transgenic mice 84 . A direct impact of this activity on cancer metastasis has not been shown yet, but the somewhat frequent overexpression of APC in certain cancer types 85 suggests that this possibility should be further investigated. FAS, widely known as an apoptosis inducer 86 , has also been shown to promote metastasis via increased cell motility in gastric cancer cell lines and mouse models 87 , as well as cell proliferation in mouse models of ovarian cancer and liver cancer 88 and cancer cell replicative immortality in breast, ovarian, colon, liver and brain cancer cell lines 89 . BRCA1, a DNA damage repair and cell cycle control protein 90 , serves as a TSG in the nucleus. Somatic and germline mutations inactivating BRCA1 are among the best-characterized alterations in breast and ovarian cancers 90 . Inactivation of BRCA1 promotes the early stages of oncogenic transformation by enabling accumulation Epithelial-to-mesenchymal transition (eMT). A process in which epithelial cells lose cell polarity and cell-cell adhesion with accompanying increases in migratory and invasive capacities; eMT occurs during embryogenesis, fibrosis and wound healing but may also be an early event in cancer metastasis.
of DNA damage and thus increasing the probability of oncogenes and TSGs acquiring somatic mutations. Mutations that disrupt or delete the carboxy-terminal domain of BRCA1, including one of the most frequent germline mutations associated with familial breast cancer (a single nucleotide insertion resulting in a frameshift in the protein: c.5382insC (p.Q1756fs)), cause sequestration of the protein in the cytoplasm, with the consequence that BRCA1 cannot perform its canonical role of DNA repair in the nucleus 91 . In addition, increased cytoplasmic levels of mutant BRCA1 can exacerbate the invasive and metastatic capabilities of breast cancer cells in vitro and are associated with increased metastasis in patients with breast cancer aged over 40 (ref. 92 ). Further, the expression of a splice variant of BRCA1 lacking the carboxy-terminal domain (BRCA1-IRIS) has been associated with more aggressive types of breast cancer 93 . This is an example of an alteration in the same gene resulting in inactivation of one of its functions but upregulation of the other, with both dysfunctions driving different stages of tumour development. A similar combination of tumour-suppressive and pro-metastatic activity has been described in the spindle-assembly checkpoint gene BUB1B 94, 95 . In addition to its well-described tumour-suppressing properties 96 , BUB1B can suppress anoikis 94 . This enables anchorage-independent survival and growth and thus promotes metastasis in lung adenocarcinomas 94 . Additionally, DDX3X [97] [98] [99] and SPOP 100,101 also act as TSGs during the initial stages of transformation but as drivers of metastasis in later stages.
Context is the key
Clearly, the impact of certain hallmarks of cancer may be dramatically different depending on multiple factors including genetic alteration, tissue of origin, environmental and microenvironmental factors and even tumour stage. For instance, apoptosis is widely recognized as one of the main activities typically associated with TSGs and protecting from malignant transformation 102 , but apoptosis can also accelerate tumour evolution and clonal expansion by creating niches within the tumour microenvironment that can be repopulated by more aggressive sub clones 103 . Cessation of initiated apoptosis may also stimulate oncogenesis. Members of the caspase protein family are known for their role in apoptotic signalling, but if cell death is initiated and then inhibited by other factors, caspases can drive cellular transformation by stimulating cell proliferation and cleaving the DNA 104 . Similarly, inactivation of DNA repair is key in cancer promotion, but a certain level of functional DNA repair is necessary to enable tumour survival, a phenomenon that underlies the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in cancers with a BRCA-related DNA repair defect (synthetic lethality) 13 . Easy access to broad information about the whole spectrum of gene functions via the CGC, while intended to help understand the mechanisms of oncogenesis, may also help characterize potential targets for therapy as research reveals the complexity of gene and tumour interactions. This increasing clarity, in combination with information about genetic alterations provided by COSMIC, should help identify new potential therapeutic targets that are specific for the cancer type, stage and genetic profile and predict possible consequences of these new therapeutic approaches.
Perspectives and challenges
Understanding the biological foundations of cancer and molecular processes involved in oncogenesis is crucial for development of new diagnostic and therapeutic procedures that would allow for better prevention and treatment of the disease. Data integrated in the CGC including the examples shown in this Review confirm that cancer cannot be explained exclusively by germline and somatic mutations acting on a single-cell level, as extracellular factors including pathogens or the microenvironment of the tissue may modify the development of cancer. However, knowledge of which genes are active, how mutations cause dysfunction of these genes and how this can drive the functional hallmarks of cancer is essential for understanding the cellular changes during oncogenesis. The CGC is intended as guidance through this complex web of information and was built as a systematic and exhaustive integration of all available data on the genes that have been found to have functional genetic impacts across all cancer types. By being strongly evidence-based and using referenced literature, the CGC defines the role of each gene in disease progression and describes which cellular processes are affected.
Functional annotations are exclusively focused on cancer-driving processes and provide three layers of information granularity. On the simplest level, annotations indicate how each gene is involved in a hallmark of cancer. This information could be used for a quick overview of gene functions or for determining how the hallmarks are affected in a patient sample or cohort. When combined with curation of disease-specific mutation profiles (from the COSMIC database), the CGC allows for fully controlled construction of functionally related gene sets for focused functional investigations and variant interpretations. On a deeper level, the gene functions that affect each of the hallmarks and the impact of mutations on protein functions are concisely described to support deeper research into specific gene functions. Finally, all information is transparently referenced, and all curated details can be independently scrutinized for additional details.
Curating the functional descriptions of CGC genes is a long-term, ongoing exercise, and the descriptions are updated when manual curation compiles enough information to illustrate the full known spectrum of cancer-related gene functions. At the time of this Review, 258 of 574 Tier 1 CGC genes have been functionally characterized, and this resource will be expanded and updated every 3 months.
Future development of the CGC will focus on expanding Tier 1 and Tier 2, as well as on improving the coverage of mutation-related dysfunctions across human cancers. The great challenge for the future is to further integrate these data with information about how specific forms of mutation alter relationships across genetic interaction networks (that is, pathways) in every tissue and how these may be affected by extracellular factors to drive disease. 
